This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haran, E. F. Articles by Degani, H. Search for Related Content PubMed PubMed Citation Articles by Haran, E. F. Articles by Degani, H.

Tamoxifen Enhances Cell Death in Implanted MCF7 Breast Cancer by Inhibiting Endothelium Growth¹

Chemical Physics Department, Weizmann Institute of Science, 76100 Rehovot [E. F. H., A. F. M., H. D.], and Department of Pathology, Sheba Medical Center at Tel Hashomer [I. G., A. H.], Israel

Magnetic resonance imaging at high spatial resolution and histochemical staining were applied to monitor the influence of tamoxifen versus estrogen on the growth, endothelial density, and extent of necrosis in tumors of MCF7 human breast cancer cells implanted in nude mice. Concomitantly with tamoxifen growth arrest, a highly significant decrease, by more than 2-fold, in the endothelial density of viable tumor regions had occurred, together with a significant increase in the extent of necrosis. The results suggest that the antiestrogenic activity of tamoxifen in breast cancer, which results in enhanced necrosis and tumor regression, is due to the inhibition of angiogenesis and of endothelial growth, thus reducing vascularization and impairing tumor perfusion.

¹ Supported in part by the Israel-U.S. Binational Science Foundation and by the Israel Academy of Sciences.

Received 7/26/94. Accepted 9/20/94.

This article has been cited by other articles:

				J. Hartman, K. Lindberg, A. Morani, J. Inzunza, A. Strom, and J.-A. Gustafsson Estrogen Receptor {beta} Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts Cancer Res., December 1, 2006; 66(23): 11207 - 11213. [Abstract] [Full Text] [PDF]

				Y. Hassid, E. Furman-Haran, R. Margalit, R. Eilam, and H. Degani Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res., April 15, 2006; 66(8): 4159 - 4166. [Abstract] [Full Text] [PDF]

				B. P. Schneider and K. D. Miller Angiogenesis of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1782 - 1790. [Full Text] [PDF]

				L. Braga, R. C. Semelka, R. Pietrobon, D. Martin, N. de Barros, and U. Guller Does Hypervascularity of Liver Metastases as Detected on MRI Predict Disease Progression in Breast Cancer Patients? Am. J. Roentgenol., May 1, 2004; 182(5): 1207 - 1213. [Abstract] [Full Text] [PDF]

				J.-P. Delille, P. J. Slanetz, E. D. Yeh, E. F. Halpern, D. B. Kopans, and L. Garrido Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study Radiology, July 1, 2003; 228(1): 63 - 69. [Abstract] [Full Text] [PDF]

				Y. Hamma-Kourbali, R. Vassy, A. Starzec, V. Le Meuth-Metzinger, O. Oudar, R. Bagheri-Yarmand, G. Perret, and M. Crepin Vascular Endothelial Growth Factor 165 (VEGF165) Activities Are Inhibited by Carboxymethyl Benzylamide Dextran That Competes for Heparin Binding to VEGF165 and VEGF165{middle dot}KDR Complexes J. Biol. Chem., October 19, 2001; 276(43): 39748 - 39754. [Abstract] [Full Text] [PDF]

				R. Bagheri-Yarmand, Y. Hamma-Kourbali, P. Bissieres, J.-F. Morere, and M. Crepin Carboxymethyl Benzylamide Dextran and Tamoxifen Combination Inhibits Tumor Growth and Angiogenesis Clin. Cancer Res., June 1, 2001; 7(6): 1805 - 1811. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				D. W. Losordo and J. M. Isner Estrogen and Angiogenesis : A Review Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 6 - 12. [Abstract] [Full Text] [PDF]

				K. L. Blackwell, Z. A. Haroon, S. Shan, W. Saito, G. Broadwater, C. S. Greenberg, and M. W. Dewhirst Tamoxifen Inhibits Angiogenesis in Estrogen Receptor-negative Animal Models Clin. Cancer Res., November 1, 2000; 6(11): 4359 - 4364. [Abstract] [Full Text] [PDF]

				G. J. Byrne, A. Ghellal, J. Iddon, A. D. Blann, V. Venizelos, S. Kumar, A. Howell, and N. J. Bundred Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis J Natl Cancer Inst, August 16, 2000; 92(16): 1329 - 1336. [Abstract] [Full Text] [PDF]

				C. L. Arteaga, K. M. Koli, T. C. Dugger, and R. Clarke Reversal of Tamoxifen Resistance of Human Breast Carcinomas In Vivo by Neutralizing Antibodies to Transforming Growth Factor-ß J Natl Cancer Inst, January 6, 1999; 91(1): 46 - 53. [Abstract] [Full Text] [PDF]

				R. K. Jain, N. Safabakhsh, A. Sckell, Y. Chen, P. Jiang, L. Benjamin, F. Yuan, and E. Keshet Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor PNAS, September 1, 1998; 95(18): 10820 - 10825. [Abstract] [Full Text] [PDF]

				N. Guthrie, A. Gapor, A. F. Chambers, and K. K. Carroll Inhibition of Proliferation of Estrogen Receptor-Negative MDA-MB-435 and -Positive MCF-7 Human Breast Cancer Cells by Palm Oil Tocotrienols and Tamoxifen, Alone and in Combination J. Nutr., March 1, 1997; 127(3): 544 - 544. [Abstract] [Full Text]